Open Access
Subscription Access
Understanding Enzyme Inhibitors: Their Dual Role as Poisons and Drugs
Abstract
Enzymes, the biological catalysts responsible for enhancing chemical reactions within living organisms, are critical for regulating life-sustaining processes. Whatever it may be, the modulation of enzyme activity is not only of interest in physiological contexts but also holds significance in pharmacology and toxicology. Enzyme inhibitors play an important role in both realms, behaving as potent poisons, therapeutic drugs and even as therapeutic enzymes themselves.
References
Whelton, P. K., Carey, R. M., Aronow, W. S., Casey, D. E., Collins, K. J., Dennison Himmelfarb, C., ... & Wright, J. T. (2018). 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Journal of the American College of Cardiology, 71(19), e127-e248.
Knežević, T., Gellineo, L., Jelaković, A., Premužić, V., Dika, Ž., Laganović, M., & Jelaković, B. (2018). Treatment of Hypertension induced albuminuria. Current pharmaceutical design, 24(37), 4404-4412.
Hradec J. (2018). Pharmacological therapy for chronic heart failure. Vnitr Lek., 64(9), 853-859.
Leru, P. M., Anton, V. F., & Bumbea, H. (2018). Nine year follow-up of a rare case of angioedema due to acquired C1-inhibitor deficiency with late onset and good response to attenuated androgen. Allergy, Asthma & Clinical Immunology, 14, 1-5.
Viberti, G., Mogensen, C.E., Groop, L.C., Pauls, J.F. (1994). Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. European Microalbuminuria Captopril Study Group, 271(4), 275-9.
Lewis, E. J., Hunsicker, L. G., Bain, R. P., & Rohde, R. D. (1993). The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. New England Journal of Medicine, 329(20), 1456-1462.
Krečak, I., Morić Perić, M., Zekanović, I., Holik, H., Coha, B., Gverić-Krečak, V., & Lucijanić, M. (2021). Beneficial effect of ACE inhibitors on kidney function in polycythemia vera. Wiener klinische Wochenschrift, 1-8.
Yao, J., Fan, S., Shi, X., Gong, X., Zhao, J., & Fan, G. (2021). Angiotensin-converting enzyme inhibitors versus angiotensin II receptor blockers on insulin sensitivity in hypertensive patients: A meta-analysis of randomized controlled trials. PloS one, 16(7), e0253492.
Salmenkari, H., Korpela, R., & Vapaatalo, H. (2021). Renin–angiotensin system in intestinal inflammation—Angiotensin inhibitors to treat inflammatory bowel diseases?. Basic & Clinical Pharmacology & Toxicology, 129(3), 161-172.
Chen, Y. J., Li, L. J., Tang, W. L., Song, J. Y., Qiu, R., Li, Q., ... & Wright, J. M. (2018). First‐line drugs inhibiting the renin angiotensin system versus other first‐line antihypertensive drug classes for hypertension. Cochrane database of systematic reviews, (11).
Patel, S., Rauf, A., Khan, H., & Abu-Izneid, T. (2017). Renin-angiotensin-aldosterone (RAAS): The ubiquitous system for homeostasis and pathologies. Biomedicine & Pharmacotherapy, 94, 317-325.
Silva, P., Brown, R. S., & Epstein, F. H. (1977). Adaptation to potassium. Kidney international, 11(6), 466-475.
Yee, A. H., Burns, J. D., & Wijdicks, E. F. (2010). Cerebral salt wasting: pathophysiology, diagnosis, and treatment. Neurosurgery Clinics, 21(2), 339-352.
Williams, B. (2016). Drug discovery in renin–angiotensin system intervention: past and future. Therapeutic advances in cardiovascular disease, 10(3), 118-125.
Yeo, W. W., Chadwick, I. G., Kraskiewicz, M., Jackson, P. R., & Ramsay, L. E. (1995). Resolution of ACE inhibitor cough: changes in subjective cough and responses to inhaled capsaicin, intradermal bradykinin and substance-P. British journal of clinical pharmacology, 40(5), 423.
Lunde, H., Hedner, T., Samuelsson, O., Lotvall, J., Andrén, L., Lindhom, L., & Wilholm, B. E. (1994). Dyspnoea, asthma, and bronchospasm in relation to treatment with angiotensin converting enzyme inhibitors. BMJ, 308(6920), 18.
Malini, P. L., Strocchi, E., Zanardi, M., Milani, M., & Ambrosioni, E. (1997). Thromboxane antagonism and cough induced by angiotensin-converting-enzyme inhibitor. The Lancet, 350(9070), 15-18.
Matchar, D. B., McCrory, D. C., Orlando, L. A., Patel, M. R., Patel, U. D., Patwardhan, M. B., ... & Gray, R. N. (2008). Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treating essential hypertension. Annals of internal medicine, 148(1), 16-29.
Ghouse, J., Ahlberg, G., Andreasen, L., Banasik, K., Brunak, S., Schwinn, M., ... & Olesen, M. S. (2021). Association of variants near the bradykinin receptor B2 gene with angioedema in patients taking ACE inhibitors. Journal of the American College of Cardiology, 78(7), 696-709.
Kifor, I., Moore, T. J., Fallo, F., Sperling, E., Chiou, C. Y., Menachery, A., & Williams, G. H. (1991). Potassium-stimulated angiotensin release from superfused adrenal capsules and enzymatically dispersed cells of the zona glomerulosa. Endocrinology, 129(2), 823-831.
Refbacks
- There are currently no refbacks.